U.S. FDA Accepts sNDA for Roflumilast Cream for PsO in Young Kids; PDUFA Date Set for June 29, 2026.
Publisher
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Dermatology Digest
- Region
- Global
- Scope
- discovery
- Published
- June 27, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Dermatology Digest
Scope: discovery
Related coverage
More related coverage
Medicaid Program; Community Engagement Requirement for Certain Individuals
Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The Food and Drug Administration (FDA) is classifying the medial knee implanted shock absorber into...
Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of...